These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 12635453)
61. Thiazolidinediones and lowered HDL cholesterol. Savage RL; Kiuru A Diabetes Care; 2005 Sep; 28(9):2329-30. PubMed ID: 16123514 [No Abstract] [Full Text] [Related]
62. Hydrochloride pioglitazone protects diabetic rats against podocyte injury through preserving glomerular podocalyxin expression. Xing Y; Ye S; Chen Y; Hu W; Chen Y Arq Bras Endocrinol Metabol; 2014 Aug; 58(6):630-9. PubMed ID: 25211446 [TBL] [Abstract][Full Text] [Related]
63. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs). Goldstein BJ Clin Ther; 2002 Aug; 24(8):1358-60; author reply 1360-2. PubMed ID: 12240785 [No Abstract] [Full Text] [Related]
64. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. Sultan A; Avignon A; Galtier F; Piot C; Mariano-Goulart D; Dupuy AM; Cristol JP Diabetes Care; 2008 Mar; 31(3):593-5. PubMed ID: 18083791 [No Abstract] [Full Text] [Related]
65. A comprehensive review of the antidiabetic agent rosiglitazone. Glazer NB; Cheatham WW Clin Ther; 2001 Feb; 23(2):307-8. PubMed ID: 11293563 [No Abstract] [Full Text] [Related]
66. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Bell DS; Ovalle F Endocr Pract; 2001; 7(2):135-8. PubMed ID: 11421558 [No Abstract] [Full Text] [Related]
67. [Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk]. Tan MH Rev Clin Esp; 2003 Jan; 203(1):33-40. PubMed ID: 12605799 [No Abstract] [Full Text] [Related]
68. Glitazones, glycemia, and global health status. Isley WL Diabetes Care; 2001 Dec; 24(12):2158-9. PubMed ID: 11723105 [No Abstract] [Full Text] [Related]
69. A word of caution regarding pioglitazone. Usman MS; Rizwan T; Ahmed F J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979 [No Abstract] [Full Text] [Related]
70. The benefits and risks of new therapies for type 2 diabetes. Asche CV; Nelson RE J Manag Care Pharm; 2008 Sep; 14(7):655-7. PubMed ID: 18774876 [No Abstract] [Full Text] [Related]
71. Potential cardiovascular effects of thiazolidinediones. Westphal SA Endocr Pract; 2001; 7(3):222-3. PubMed ID: 11421570 [No Abstract] [Full Text] [Related]
73. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. King AB Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952 [No Abstract] [Full Text] [Related]
74. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022 [TBL] [Abstract][Full Text] [Related]
75. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. King AB; Armstrong DU Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617 [TBL] [Abstract][Full Text] [Related]
76. [Clinical efficacy of Pioglitazone (AD-4833)]. Kaneko T; Baba S Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458 [No Abstract] [Full Text] [Related]
77. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Jun JK; Gong WC; Mathur R Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453 [No Abstract] [Full Text] [Related]
78. Actos (pioglitazone): a new treatment for type 2 diabetes. Lawrence JM; Reckless JP Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129 [TBL] [Abstract][Full Text] [Related]